RxDoctor Payments Data

Shuang Wang, MD

Internal Medicine · Philadelphia, PANPI 1447548052

Payments from drug & device makers

$2,395in general payments, 2019–2025

Across 112 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • AbbVie$521
  • GSK$190
  • Aimmune Therapeutics, Inc.$183
  • AstraZeneca$56
  • Merck$40
  • plus $288 from 14 others

What the payments were for

  • Food & beverage$2,387100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,395 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$140,634
Medicare patients
205
Services billed
2,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl328$211,390
JanuviaSitagliptin Phosphate147$117,677
JardianceEmpagliflozin109$93,373
TrulicityDulaglutide73$70,189
CreonLipase/Protease/Amylase27$45,562
LinzessLinaclotide63$36,639
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$34,932
EliquisApixaban52$33,562
FarxigaDapagliflozin Propanediol36$26,298
Tenofovir Disoproxil Fumarate64$23,480
EntrestoSacubitril/Valsartan23$16,918
TradjentaLinagliptin22$16,564
OzempicSemaglutide18$16,507
Breo ElliptaFluticasone/Vilanterol37$15,441
Entecavir19$14,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$40$129,606164 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$14$123,159153 claims
AbbVieCreon, Linzess, Restasis$521$92,996107 claims
GSKTrelegy Ellipta, Breo Ellipta$190$50,37491 claims
PfizerEliquis$14$33,56252 claims
AstraZenecaFarxiga$56$26,29836 claims
Novo NordiskOzempic$13$16,50718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →